Health News   Health Library   Health Topics   Healthy Living   HealthLink
Today's Headlines    Health Alerts    Health News Feature   
Future of Medicine    Health Observances    Product Recalls
Illnesses & Conditions    Drug Guide    FDA Drug Approvals    Complementary Medicine    Medical Tests   
Self-Help Resources    Medline Search
Allergies    Asthma    Back Pain    Cancer    Caregiver    Depression    Diabetes    Digestive Disorders
Heart Disease    Kidney Disease    Men's Health    Parenting    Pregnancy    Senior's Health
Stress    Stroke    Women's Health
Fitness    Nutrition    Mind & Body    Family & Home







Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

Xyzal Approved for Younger Kids


Antihistamine sanctioned for children as young as 6 months

TUESDAY, Aug. 25 (HealthDay News) -- The antihistamine Xyzal (levocetirizine dihydrochloride) has been approved for children aged six months and older for indoor allergies and hives, drug makers UCB and Sanofi-Aventis said.

The medication, available as a liquid or pill, had been approved previously for people aged six years and older. The expanded approval also sanctions the drug's use to treat outdoor allergies in children aged two years and older.

Side effects of the medication may include fatigue, sore throat and dry mouth. Younger children may have additional adverse effects including fever, diarrhea, vomiting, ear infections and constipation, the drug makers said in a news release.

More information

The FDA has more information about this drug's approval history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay


Powered by Healthvision